Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ijcard.2015.05.105 http://scihub22266oqcxt.onion/10.1016/j.ijcard.2015.05.105 26011408!ä!26011408 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 300.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 300.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26011408.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Int+J+Cardiol 2015 ; 195 (ä): 19-26 Nephropedia Template TP {{tp|p=26011408|t=2015. Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension |pdf=|usr=}}{{26011408}} gab.com Text Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension JO: Int J Cardiol http://www.kidney.de/pget.php?&tw=1&pmid=26011408 #FOAvip BACKGROUND: Riociguat is a soluble guanylate cyclase stimulator approved for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). The objective of this study was to evaluate the change of right heart size and function assessed by echocardiography during long-term treatment with riociguat. METHODS: We assessed patients who started riociguat treatment (1.0-2.5mg tid) within the trials PATENT, PATENTplus, EAS and CHEST and continued for 3-12 months. Echocardiography, 6-minute walking distance (6MWD) and further clinical parameters were analyzed at baseline, after 3, 6 and 12 months. Right heart catheterization was performed at baseline and after 3 months. For missing data we performed the last and baseline observation carried forward (LOCF, BOCF) method as sensitivity analyses. RESULTS: Thirty-nine patients (21 PAH, 18 CTEPH, mean pulmonary arterial pressure 43 +/- 2 mmHg, PVR 600 +/- 43 dyn * s * cm(-5), 56.4% treatment-naive) were included. Mean right ventricular (RV) area significantly decreased after 3 (-2.1 +/- 3.9 cm(2), equals -7.4 +/- 15.3%, p = 0.002), 6 (-4.2 +/- 3.2 cm(2), equals -16.1 +/- 11.5%, p < 0.001) and 12 months (-5.9 +/- 4.6 cm(2), equals -22.1 +/- 14.2%, p < 0.001) compared to baseline. Right atrial area significantly decreased after 12 months (-3.5 +/- 4.1cm(2), equals -16.8 +/- 19.2%, p < 0.001) and TAPSE significantly improved after 6 (+ 2 +/- 4.7, equals 12 +/- 25.8%, p = 0.025) and 12 months (+ 3.6 +/- 5.4, equals 21.0 +/- 29.6%, p = 0.002). Furthermore, RV wall thickness and 6MWD significantly improved after 3, 6 and 12 months (p < 0.05). Invasive hemodynamics significantly improved after 3 months. Both LOCF and BOCF showed similar significance and lower effect sizes. CONCLUSION: Long-term treatment with riociguat significantly reduced right heart size and improved RV function in PAH and CTEPH. Further prospective studies are needed to confirm these results. Twit Text FOAVip Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension ????Int J Cardiol http://www.kidney.de/pget.php?&tw=1&pmid=26011408 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26011408 #FOAvip English Wikipedia <ref>{{Cite pmid|26011408}}</ref> Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension #MMPMID26011408 Marra AM; Egenlauf B; Ehlken N; Fischer C; Eichstaedt C; Nagel C; Bossone E; Cittadini A; Halank M; Gall H; Olsson KM; Lange TJ; Grunig E Int J Cardiol 2015[Sep]; 195 (ä): 19-26 PMID26011408show ga BACKGROUND: Riociguat is a soluble guanylate cyclase stimulator approved for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). The objective of this study was to evaluate the change of right heart size and function assessed by echocardiography during long-term treatment with riociguat. METHODS: We assessed patients who started riociguat treatment (1.0-2.5mg tid) within the trials PATENT, PATENTplus, EAS and CHEST and continued for 3-12 months. Echocardiography, 6-minute walking distance (6MWD) and further clinical parameters were analyzed at baseline, after 3, 6 and 12 months. Right heart catheterization was performed at baseline and after 3 months. For missing data we performed the last and baseline observation carried forward (LOCF, BOCF) method as sensitivity analyses. RESULTS: Thirty-nine patients (21 PAH, 18 CTEPH, mean pulmonary arterial pressure 43 +/- 2 mmHg, PVR 600 +/- 43 dyn * s * cm(-5), 56.4% treatment-naive) were included. Mean right ventricular (RV) area significantly decreased after 3 (-2.1 +/- 3.9 cm(2), equals -7.4 +/- 15.3%, p = 0.002), 6 (-4.2 +/- 3.2 cm(2), equals -16.1 +/- 11.5%, p < 0.001) and 12 months (-5.9 +/- 4.6 cm(2), equals -22.1 +/- 14.2%, p < 0.001) compared to baseline. Right atrial area significantly decreased after 12 months (-3.5 +/- 4.1cm(2), equals -16.8 +/- 19.2%, p < 0.001) and TAPSE significantly improved after 6 (+ 2 +/- 4.7, equals 12 +/- 25.8%, p = 0.025) and 12 months (+ 3.6 +/- 5.4, equals 21.0 +/- 29.6%, p = 0.002). Furthermore, RV wall thickness and 6MWD significantly improved after 3, 6 and 12 months (p < 0.05). Invasive hemodynamics significantly improved after 3 months. Both LOCF and BOCF showed similar significance and lower effect sizes. CONCLUSION: Long-term treatment with riociguat significantly reduced right heart size and improved RV function in PAH and CTEPH. Further prospective studies are needed to confirm these results. |Adult[MESH] |Aged[MESH] |Atrial Function, Right/*drug effects[MESH] |Chronic Disease[MESH] |Echocardiography[MESH] |Exercise Test[MESH] |Female[MESH] |Guanylate Cyclase/*metabolism[MESH] |Heart Atria[MESH] |Heart Ventricles/anatomy & histology[MESH] |Humans[MESH] |Hypertension, Pulmonary/diagnostic imaging/*drug therapy/physiopathology[MESH] |Male[MESH] |Middle Aged[MESH] |Pulmonary Embolism/diagnostic imaging/*drug therapy/physiopathology[MESH] |Pyrazoles/*therapeutic use[MESH] |Pyrimidines/*therapeutic use[MESH] |Treatment Outcome[MESH] |Ventricular Function, Right/*drug effects[MESH]Change of right heart size and function by long-term therapy with rioc(epmc).pdf DeepDyve Pubget Overpricing